Commercial supply of the 12-year contract manufacturing agreement, following the completion of the required tech-transfer project, is expected to commence in early 2023 Based on current market sales volume, the new product is estimated to add approximately $8 million to $10 million in annual revenues to Kamada Gross margin level of the new product is […]
REHOVOT, Israel – December 2, 2019 — Kamada Ltd. (Nasdaq: KMDA; TASE: KMDA.TA), today announced that it has entered into an agreement with Alvotech, a global biopharmaceutical company, to commercialize Alvotech’s portfolio of six biosimilar product candidates in Israel, upon receipt of regulatory approval from the Israeli Ministry of Health (IMOH). Kamada leverages its expertise […]
Total Revenues for Third Quarter and First Nine Months of 2019 were $33.1 Million and $95.1 Million, Respectively, Compared to $15.0 Million and $66.3 Million in the Respective Periods in 2018. As a Reminder, Kamada’s Third Quarter 2018 Performance was Impacted by the Then Labor Strike in the Company’s Manufacturing Facility. Gross Profit for Third […]
Rehovot, Israel, November 7, 2019 — Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, today announced that it will release financial results for the third quarter and nine months ended September 30, 2019, prior to the open of the U.S. financial markets on Wednesday, November 13, 2019. Kamada management will host an […]
The Successful Study was Basis for U.S. Food & Drug Administration Approval of KEDRAB® in 2017 Post-Marketing U.S. Pediatric Study Data Expected in 2H ‘2020 Abstract will be Presented at the Upcoming 2019 Rabies In The Americas (RITA) Conference Rehovot, Israel and Fort Lee, NJ, USA– October 29, 2019 – Kamada Ltd. (NASDAQ: KMDA; TASE: […]
REHOVOT, Israel – September 24, 2019 – Kamada Ltd. (NASDAQ and TASE: KMDA), a plasma-derived protein therapeutics company, announced today that Amir London, Chief Executive Officer, will provide a corporate overview at the 2019 Cantor Global Healthcare Conference, being held October 2-4, 2019, in New York City. The presentation will take place on Friday, October […]
Based on the Extended Term, Kamada Projects Revenues from Sales of GLASSIA to Takeda During 2019-2021 to be in the Range of $155 Million to $180 Million Based on Current GLASSIA U.S. Sales and Forecasted Growth, Kamada Projects to Receive Royalties from Takeda in the Range of $10 Million to $20 Million Per Year from […]
REHOVOT, Israel – August 8, 2019 — Kamada Ltd. (Nasdaq: KMDA; TASE: KMDA.TA), a plasma-derived protein therapeutics company, reports that it is currently in discussions with Takeda to extend the period prior to transitioning the manufacture of GLASSIA, Kamada’s proprietary product for the treatment of Alpha-1 Antitrypsin Deficiency, to Takeda. Kamada will provide additional information […]
Total Revenues for Second Quarter of 2019 were $35.3 Million, a 4% Increase Year-Over-Year Total Revenues for First Six Months of 2019 were $62.1 Million, a 21% Increase Year-Over-Year Gross Profit for Second Quarter and First Six Months of 2019 was $13.6 million and $24.8 Million, Respectively, a 27% and 40% Increase Year-Over-Year, Respectively Net […]
Click here for the financial reports Click here for the investor call webcast REHOVOT, Israel – May 14, 2019 — Kamada Ltd. (Nasdaq: KMDA; TASE: KMDA.TA), a plasma-derived protein therapeutics company, today announced financial results for the three months ended March 31, 2019. “We are extremely pleased with our solid start to 2019,” said Amir […]